Mirxes Holding Company Limited (HKG:2629)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Early Detection and Precision Multi-Omics	17.65M	17.48M	10.27M
Infectious Diseases	2.63M	6.70M	7.49M
Total	20.28M	24.19M	17.76M

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Singapore	12.12M	14.93M	6.79M
PRC	6.93M	5.80M	3.51M
Indonesia	4.70K	911.07K	2.48M
Others	1.13M	987.26K	245.87K
Philippines	85.67K	1.49M	2.54M
Switzerland	-	70.72K	1.02M
Vietnam	-	-	1.18M
Total	20.28M	24.19M	17.76M

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 29, 2026

Data Sources Report a data error